Brokerages Set Xenon Pharmaceuticals Inc. (NASDAQ:XENE) PT at $77.20

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have been assigned an average recommendation of “Buy” from the seventeen ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $77.20.

A number of research analysts have recently commented on XENE shares. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Morgan Stanley set a $97.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Royal Bank Of Canada lifted their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, May 8th.

Xenon Pharmaceuticals Price Performance

NASDAQ XENE opened at $60.30 on Thursday. Xenon Pharmaceuticals has a 1-year low of $30.00 and a 1-year high of $63.95. The company has a market capitalization of $5.83 billion, a P/E ratio of -12.83 and a beta of 0.61. The business has a 50 day moving average price of $54.83 and a 200 day moving average price of $50.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the business posted ($0.83) earnings per share. On average, research analysts expect that Xenon Pharmaceuticals will post -4.92 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gillian Cannon sold 1,190 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director directly owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This trade represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of XENE. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at about $32,000. Blue Trust Inc. boosted its holdings in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals in the 4th quarter worth approximately $33,000. Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $39,000. Finally, Osaic Holdings Inc. raised its stake in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.